Prakt. lékáren. 2015; 11(4): 144-147

How are new drugs developed

Lenka Součková1, Hana Kostková1, Regina Demlová1,2
1 Farmakologický ústav LF MU Brno

The process of research and development of new drugs is very time and financially demanding. Since the start of research to placing the

new drug on the market the development of the one new drug takes 12–15 years and the average cost is worth about – 2,6 billions. USD.

The constantly increasing time and financial demand is closely linked with efforts to be marketed safer and more effective drugs and

associated requirements, such as detailed and prolonged preclinical safety testing. The individual successive stages of drug development

(in silico, in vitro, in vivo and in homo) are described in the article. The article discusses the characteristics of the individual phases of

clinical trials for human medicines in more detail.

Keywords: drug research and development, preclinical tests, clinical trials, registration

Published: September 15, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Součková L, Kostková H, Demlová R. How are new drugs developed. Praktické lékárenství. 2015;11(4):144-147.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Park BK, Boobis A, Clarke S, et al. Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov 2011; 10(4): 292-306. Go to original source... Go to PubMed...
    2. Chodera JD, Mobley DL, Shirts MR, et al. Alchemical free energy methods for drug discovery: progress and challenges. Curr Opin Struct Biology 2011; 21(2): 150-160. Go to original source... Go to PubMed...
    3. Macarron R, et al. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 2011; 10(3): 188-195. Go to original source... Go to PubMed...
    4. Shlonimskaya N, et al. An Application of Computer-Aided Molecular Design (CAMD) Using the Signature Molecular Descriptor-Part 2. Evaluating Newly Identified Surface Tension-Reducing Substances for Potential Use as Shrinkage-Reducing Admixtures. J Am Ceram Soc 2014; 97(2): 378-385. Go to original source...
    5. Liaw A, Svetnik V. QSAR modeling: prediction of biological activity from chemical structure. Statistical Methods for Evaluating Safety in Medical Product Development 2015: 66-83. Go to original source...
    6. Nicolau KC. Advancing the Drug Discovery and Development Process. Angew. Chem. Int. Ed 2014; 53: 9128-9140. doi: 10.1002/anie.201404761. Go to original source... Go to PubMed...
    7. Kuchař M. Výzkum a vývoj léčiv. 1st ed. Vysoká škola chemicko-technologická v Praze, Praha 2008. ISBN 978-80-7080-677-7.
    8. Djulbegovic B, Hozo I, Ioannidis JA. Improving the Drug Development Process: More Not Less Randomized Trials JAMA 2014; 311(4): 355-356. doi: 10.1001/jama.2013.283742. Go to original source... Go to PubMed...
    9. Avorn J. The $2.6 Billion Pill - Methodologic and Policy Considerations. The New England Journal of Medicine 2015; 372(20): 1877-1879. Go to original source... Go to PubMed...
    10. Nwaka S, Ridley RG. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat Rev Drug Discov 2003; 2(11): 919-928. Go to original source... Go to PubMed...
    11. Svobodník A, Demlová R, Pecen L, a kol. Klinické studie v praxi, vyd. Facta Medica s. r. o., 2014, ISBN: 978-80-904731-8-8.
    12. Berthelsen R, Sjögren E, Jacobsen J, Kristensen J, Holm R, Abrahamsson B, Müllertz A. Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs a fenofibrate case example. International journal of pharmaceutics 2014; 473(1): 356-365. Go to original source... Go to PubMed...
    13. Mangipudy R, Burkhardt J, Kadambi VJ. Use of animals for toxicology testing is necessary to ensure patient safety in pharmaceutical development. Regul Toxicol Pharmacol 2014; 70: 439-441. Go to original source... Go to PubMed...
    14. Silverman M. Clinical Trial End Points At Different Phases of Clinical Development 2011 https://biostrategics.wordpress.com/2011/02/28/clinical-trial-end-points-at-different-phases-of-clinical-development/16-04-2015.
    15. Demlová R, Říhová B, Grycová Z. Životní cyklu s léčiv. Klinické hodnocení a registrace léčivých přípravků, farmakovigilance a stanovování cen a úhrad léčiv. Brno: Masarykova univerzita, LF: 2014: 25.
    16. http://www.sukl.cz/leciva/phv-3-verze-317-04-2015.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.